Search Results 51-60 of 21256 for B cell lymphomas
In a study of axicabtagene ciloleucel (axi-cel) CAR-T cell therapy for relapsed or refractory aggressive B-cell lymphoma, 30-day responses were comparable ...
Monoclonal B-cell lymphocytosis (MBL) causes an increased number of a type of lymphocyte, called B lymphocytes, in the blood. ... B-cell lymphoma. This is ...
Clinical Trials · Dose-Reduced Consolidation Radiation Therapy In Patients With Diffuse Large B-cell Lymphoma (DLBCL) · More about research at Mayo Clinic · Mayo ...
ZUMA-7 led to the approval of axicabtagene ciloleucel for second line treatment of large B-cell lymphoma after showing better outcomes compared with ...
B-cell lymphomas are a heterogeneous group of neoplasms that arise from lymphocytes and produce tumors in the lymph nodes, lymphatic organs and extranodal ...
... lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma starts in germ-fighting white blood cells called B lymphocytes. Hodgkin lymphoma is highly treatable and ...
Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells.
Mayo Clinic doctors and researchers are studying primary mediastinal large B-cell lymphoma (PMBCL) to look for new ways to improve diagnosis and treatment for ...
— The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study ...
A Study To Determine The Outcomes Of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy ... - B-ALL ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.